Effectiveness of MF59™ Adjuvanted Influenza A(H1N1)pdm09 Vaccine in Risk Groups in the Netherlands

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Wijnans, Leonoor ^a,b   Dieleman, Jeanne ^a   Voordouw, Bettie ^b   Sturkenboom, Miriam ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MEDICINES EVALUATION BOARD   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; MIFAMURTIDE; IMMUNOLOGICAL ADJUVANT; MF59 OIL EMULSION; POLYSORBATE; SQUALENE;

2009 H1N1 INFLUENZA; ADJUVANT THERAPY; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; FEMALE; FLU LIKE SYNDROME; HELP SEEKING BEHAVIOR; HUMAN; INFECTION PREVENTION; INFECTION RISK; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NETHERLANDS; PANDEMIC INFLUENZA; POPULATION RISK; PRESCHOOL CHILD; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SEASONAL INFLUENZA; SINGLE DRUG DOSE; TREATMENT OUTCOME; ADOLESCENT; IMMUNOLOGY; INFANT; INFLUENZA VIRUS A H1N1; INFLUENZA, HUMAN; MIDDLE AGED; RETROSPECTIVE STUDY; VACCINATION; VERY ELDERLY; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NETHERLANDS; POLYSORBATES; RETROSPECTIVE STUDIES; SQUALENE; VACCINATION; YOUNG ADULT;

EID: 84876982504     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063156     Document Type: Article

References (24)

1. Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, et al. (2006) Strategies for mitigating an influenza pandemic Nature. 442: 448-452.
2. Johansen K, Nicoll A, Ciancio BC, Kramarz P (2009) Pandemic influenza A(H1N1) 2009 vaccines in the European Union. Euro Surveill 14: pii: 19361.
3. European Medicines Agency (2010) Summary of Product Characteristics for Focetria, Influenza vaccine H1N1v (surface antigen, inactivated, adjuvanted). Available: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000710/WC500023749.pdf. Accessed 2013 Jan 4.
4. Steens A, Wijnans E, Dieleman J, Sturkenboom M, van der Sande M, et al. (2011) Effectiveness of a MF-59TM-adjuvanted pandemic influenza vaccine to prevent 2009 influenza A/H1N1-related hospitalisation; a matched case-control study. BMC Infect Dis 11: 196.
5. Castilla J, Morán J, Martínez-Artola V, Fernández-Alonso M, Guevara M, et al. (2011) Effectiveness of the monovalent influenza A(H1N1)2009 vaccine in Navarre, Spain, 2009-2010: Cohort and case-control study. Vaccine 29: 5919-5924.
6. Song JY, Cheong HJ, Heo JY, Noh JY, Choi WS, et al. (2011) Effectiveness of the pandemic influenza A/H1N1 2009 monovalent vaccine in Korea. Vaccine 29: 1395-1398.
7. Vlug A, van der Lei J, Mosseveld B, van Wijk M, van der Linden P, et al. (1999) Postmarketing surveillance based on electronic patient records: the IPCI project. Methods Inf Med 38: 339-344.
8. van der Lei J, Duisterhout JS, Westerhof HP, van der Does E, Cromme PVM, et al. (1993) The Introduction of Computer-based Patient Records in the Netherlands. Annals of Internal Medicine 119: 1036-1041.
9. Voordouw BCG, Sturkenboom MCJM, Dieleman JP, Stijnen T, van der Lei J, et al. (2006) Annual Influenza Vaccination in Community-Dwelling Elderly Individuals and the Risk of Lower Respiratory Tract Infections or Pneumonia. Arch Intern Med 166: 1980-1985.
10. European Commission (2009) Commission Decision of 30 April 2009 amending Decision 2002/253/EC laying down case definitions for reporting communicable diseases to the Community network under Decision No 2119/98/EC of the European Parliament and of the Council. Official Journal of the European Union. Available: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:110:0058:0059:EN:PDF. Accessed 2013 Jan 4.
11. Coordination Group for Mutual Recognition and Decentralised Procedures- Human (2009) Core SPC for trivalent influenza vaccines. Available: http://www.hma.eu/uploads/media/Core_SPCPL_Influenza_Vaccines_2008_11-Clean.pdf. Accessed 2013 Jan 4.
12. Monto AS, Ansaldi F, Aspinall R, McElhaney JE, Montaño LF, et al. (2009) Influenza control in the 21st century: Optimizing protection of older adults. Vaccine 27: 5043-5053.
13. Hancock K, Veguilla V, Lu X, Zhong W, Butler E, et al. (2009) Cross-Reactive Antibody Responses to the 2009 Pandemic H1N1 Influenza Virus N Engl J Med. 361: 1945-1952.
14. Örtqvist A, Berggren I, Insulander M, de Jong B, Svenungsson B, (2011) Effectiveness of an Adjuvanted Monovalent Vaccine Against the 2009 Pandemic Strain of Influenza A(H1N1)v in Stockholm County, Sweden. Clin Infect Dis 52: 1203-1211.
15. Andrews NJ, Waight P, Yung CF, Miller E, (2011) Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. J Infect Dis 203: 32-39.
16. Skowronski DM, Janjua NZ, De Serres G, Hottes TS, Dickinson JA, et al. (2011) Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. BMJ 342: doi: http://dx.doi.org/10.1136/bmj.c7297.
17. Wichmann O, Stocker P, Poggensee G, Altmann D, Walter D, et al. (2010) Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010. Euro Surveill 15: pii: 19561.
18. Hardelid P, Fleming DM, McMenamin J, Andrews NJ, Robertson C, et al. (2011) Effectiveness of pandemic and seasonal influenza vaccine in preventing pandemic influenza A(H1N1)2009 infection in England and Scotland 2009-2010. Euro Surveill 16: doi:pii = 19763.
19. Uphoff H, an der Heiden M, Schweiger B, Campe H, Beier D, et al. (2011) Effectiveness of the AS03-Adjuvanted Vaccine against Pandemic Influenza Virus A/(H1N1) 2009- A Comparison of Two Methods; Germany, 2009/10. PLoS ONE 6: e19932 doi: 10.1371/journal.pone.0019932.
20. Pelat C, Falchi A, Carrat F, Mosnier A, Bonmarin I, et al. (2011) Field effectiveness of pandemic and 2009-2010 seasonal vaccines against 2009-2010 A(H1N1) Influenza: estimations from surveillance data in France. PLoS ONE 6: e19621 doi: 10.1371/journal.pone.0019621.
21. Simpson CR, Ritchie LD, Robertson C, Sheikh A, McMenamin J, (2010) Vaccine effectiveness in pandemic influenza- primary care reporting (VIPER): an observational study to assess the effectiveness of the pandemic influenza A (H1N1)v vaccine. Health Technol Assess 14: 313-346.
22. Valenciano M, Kissling E, Cohen JM, Oroszi B, Barret AS, et al. (2011) Estimates of Pandemic Influenza Vaccine Effectiveness in Europe, 2009-2010: Results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) Multicentre Case-Control Study. PLoS Med 8: e1000388 doi: 10.1371/journal.pmed.1000388.
23. Puig-Barberà J, Arnedo-Pena A, Pardo-Serrano F, Tirado-Balaguer MD, Pérez-Vilar S, et al. (2010) Surveillance and Vaccine Evaluation Group during the autumn 2009 H1N1 pandemic wave in Castellón, Spain. Effectiveness of seasonal 2008-2009, 2009-2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellón, Spain. A test-negative, hospital-based, case-control study. Vaccine 28: 7460-7467.
24. Savulescu C, Jimenez-Jorge S, de Mateo S, Pozo F, Casas I, et al. (2011) Using surveillance data to estimate pandemic vaccine effectiveness against laboratory confirmed influenza A(H1N1)2009 infection: two case-control studies, Spain, season 2009-2010. BMC Public Health 11: 899 doi: 10.1186/1471-2458-11-899.